PL3377061T3 - Mirabegron do leczenia chorób siatkówki - Google Patents
Mirabegron do leczenia chorób siatkówkiInfo
- Publication number
- PL3377061T3 PL3377061T3 PL16812992T PL16812992T PL3377061T3 PL 3377061 T3 PL3377061 T3 PL 3377061T3 PL 16812992 T PL16812992 T PL 16812992T PL 16812992 T PL16812992 T PL 16812992T PL 3377061 T3 PL3377061 T3 PL 3377061T3
- Authority
- PL
- Poland
- Prior art keywords
- mirabegron
- volleyball
- diseases
- treatment
- volleyball diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1561067A FR3043555B1 (fr) | 2015-11-17 | 2015-11-17 | Mirabegron pour le traitement de maladies retiniennes |
| EP16812992.2A EP3377061B1 (fr) | 2015-11-17 | 2016-11-17 | Mirabégron pour le traitement de maladies rétiniennes |
| PCT/FR2016/052981 WO2017085407A1 (fr) | 2015-11-17 | 2016-11-17 | Mirabégron pour le traitement de maladies rétiniennes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3377061T3 true PL3377061T3 (pl) | 2021-07-19 |
Family
ID=55236634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16812992T PL3377061T3 (pl) | 2015-11-17 | 2016-11-17 | Mirabegron do leczenia chorób siatkówki |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11717513B2 (pl) |
| EP (1) | EP3377061B1 (pl) |
| JP (1) | JP6908616B2 (pl) |
| KR (1) | KR102642795B1 (pl) |
| CA (1) | CA3005527C (pl) |
| DK (1) | DK3377061T3 (pl) |
| ES (1) | ES2860767T3 (pl) |
| FR (1) | FR3043555B1 (pl) |
| IL (1) | IL259381B (pl) |
| PL (1) | PL3377061T3 (pl) |
| PT (1) | PT3377061T (pl) |
| WO (1) | WO2017085407A1 (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018112154A1 (en) * | 2016-12-15 | 2018-06-21 | Codiak Biosciences, Inc. | Methods of measuring exosomes using intrinsic fluorescence |
| WO2022174310A1 (en) * | 2021-02-22 | 2022-08-25 | The University Of Sydney | Wound healing compositions |
| IT202300021417A1 (it) | 2023-10-13 | 2025-04-13 | Univ Pisa | Agonisti o attivatori del recettore adrenergico beta-3 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6441047B2 (en) * | 1995-11-17 | 2002-08-27 | Alcon Manufacturing Ltd.. | Combination therapy for treating glaucoma |
| KR100506568B1 (ko) * | 1997-10-17 | 2006-04-21 | 아스텔라스세이야쿠 가부시키가이샤 | 아미드유도체및이의염,및이를포함하는약제학적제제 |
| US7342117B2 (en) | 2001-10-30 | 2008-03-11 | Astellas Pharma Inc. | α-form or β-form crystal of acetanilide derivative |
| JP2005517684A (ja) * | 2001-12-21 | 2005-06-16 | キング ファーマシューティカルズ リサーチ アンド ディベロップメント インコーポレイテッド | チロシル誘導体及びｐ２ｘ７受容体モジュレーターとしてのそれらの使用 |
| WO2005041892A2 (en) * | 2003-11-03 | 2005-05-12 | Cornell Research Foundation, Inc | Purine receptor inhibition as a therapeutic strategy in spinal cord and brain |
| AU2005306325A1 (en) * | 2004-11-22 | 2006-05-26 | King Pharmaceuticals Research & Development Inc. | Enhancing treatment of HIF-1 mediated disorders with adenosine A3 receptor agonists |
| US20090220516A1 (en) * | 2005-06-22 | 2009-09-03 | Alan Laties | Neuroprotection of retinal ganglion cells |
| CA2665490C (en) * | 2006-10-03 | 2014-06-17 | The Trustees Of The University Of Pennsylvania | Method for treatment of macular degeneration |
| GB0713686D0 (en) * | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
| US8586760B2 (en) * | 2009-06-15 | 2013-11-19 | Auspex Pharmaceuticals, Inc. | Aminothiazole modulators of beta-3-adrenoreceptor |
| CA2792407A1 (en) * | 2010-03-08 | 2011-09-15 | The University Of Tennessee Research Foundation | Beta-adrenergic receptor agonists and uses thereof |
| EP2701719A4 (en) * | 2011-04-28 | 2015-04-22 | Claire Mitchell | METHOD FOR TREATING MACULAR OBGENATION BY MODULATION OF P2Y12 OR P2X7 RECEPTORS |
| US9655885B2 (en) * | 2011-05-18 | 2017-05-23 | Dr. Reddy's Laboratories Ltd. | Amorphous mirabegron and processes for crystal forms of mirabegron |
| EP2709993A4 (en) * | 2011-05-18 | 2015-02-25 | Reddys Lab Ltd Dr | AMORPHIC MIRABEGRON AND METHOD FOR CRYSTALLINE FORMS OF MIRABEGRON |
| ES2796737T3 (es) * | 2012-10-17 | 2020-11-30 | Inst Nat Sante Rech Med | Métodos y composiciones farmacéuticas para el tratamiento de la degeneración macular relacionada con la edad (AMD) |
-
2015
- 2015-11-17 FR FR1561067A patent/FR3043555B1/fr not_active Expired - Fee Related
-
2016
- 2016-11-17 EP EP16812992.2A patent/EP3377061B1/fr active Active
- 2016-11-17 PT PT168129922T patent/PT3377061T/pt unknown
- 2016-11-17 US US15/777,078 patent/US11717513B2/en active Active
- 2016-11-17 WO PCT/FR2016/052981 patent/WO2017085407A1/fr not_active Ceased
- 2016-11-17 KR KR1020187016045A patent/KR102642795B1/ko active Active
- 2016-11-17 CA CA3005527A patent/CA3005527C/fr active Active
- 2016-11-17 PL PL16812992T patent/PL3377061T3/pl unknown
- 2016-11-17 ES ES16812992T patent/ES2860767T3/es active Active
- 2016-11-17 DK DK16812992.2T patent/DK3377061T3/da active
- 2016-11-17 JP JP2018544436A patent/JP6908616B2/ja active Active
-
2018
- 2018-05-15 IL IL259381A patent/IL259381B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3005527A1 (fr) | 2017-05-26 |
| FR3043555B1 (fr) | 2019-10-25 |
| WO2017085407A1 (fr) | 2017-05-26 |
| DK3377061T3 (da) | 2021-04-06 |
| KR102642795B1 (ko) | 2024-03-04 |
| US11717513B2 (en) | 2023-08-08 |
| EP3377061B1 (fr) | 2020-12-30 |
| EP3377061A1 (fr) | 2018-09-26 |
| IL259381A (en) | 2018-07-31 |
| US20180353482A1 (en) | 2018-12-13 |
| ES2860767T3 (es) | 2021-10-05 |
| KR20180094879A (ko) | 2018-08-24 |
| IL259381B (en) | 2021-10-31 |
| PT3377061T (pt) | 2021-04-05 |
| CA3005527C (fr) | 2025-05-27 |
| JP2018533631A (ja) | 2018-11-15 |
| JP6908616B2 (ja) | 2021-07-28 |
| FR3043555A1 (fr) | 2017-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3212233T3 (da) | Kombinationsterapi til behandling af sygdom | |
| DK3347030T3 (da) | Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme | |
| LT3283527T (lt) | Kompleksinė terapija vėžio gydymui | |
| EP3291824C0 (en) | ANTIMICROBIAL THERAPY | |
| DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
| LT3334422T (lt) | Kanabidiolio rūgšties panaudojimas epilepsijos gydymui | |
| PL3265053T3 (pl) | Sposoby leczenia skóry | |
| HUE059694T2 (hu) | Készítmény rák kezelésére | |
| LT3206715T (lt) | Kanabidiolio naudojimas tuberozinės sklerozės komplekso gydymui | |
| HUE056287T2 (hu) | Pancreatitis kezelése | |
| DK3107563T3 (da) | Glycomålrettede terapeutiske midler | |
| MA39483A (fr) | Agents thérapeutiques cibles | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DK3373874T4 (da) | Medicinsk forbinding | |
| LT3390390T (lt) | Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui | |
| HUE050944T2 (hu) | Kezelési eljárás tradipitant alkalmazásával | |
| EP3375108A4 (en) | SELECTIVE WIFI | |
| IL256103B (en) | Compositions and methods for treating celiac sprue disease | |
| IL257355B (en) | Selection of patients for combination therapy | |
| IL257764B (en) | Methods for treatment of diseases | |
| PL3393468T3 (pl) | Metody leczenia niedoboru odporności | |
| LT3119384T (lt) | Intrahepatinių cholestazinių ligų gydymas | |
| DK3408265T3 (da) | Terapeutiske forbindelser | |
| IL254825A0 (en) | Methods of treatment with taselisib | |
| EP3597225A4 (en) | TREATMENT PROCESS |